Insiders who reported open-market trades in the last 12 months at the companies Eben Tessari files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Sanj K. Patel - $39.43M in KNSA purchases and sales in the last 12 months
John F. Paolini - $8.00M in KNSA purchases and sales in the last 12 months
Mark Ragosa - $3.78M in KNSA purchases and sales in the last 12 months
Michael R. Megna - $2.64M in KNSA purchases and sales in the last 12 months
Barry D. Quart - $1.85M in KNSA purchases and sales in the last 12 months
G. Bradley Cole - $299K in KNSA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Eben Tessari is a corporate insider, tracked as CHIEF STRATEGY OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Eben Tessari last file a Form 4?
The most recent primary Form 4 on record is dated 8 April 2026, one of 15 filings going back to 2024.
Has Eben Tessari been buying or selling stock?
Recorded transactions: 0 open-market purchases and 19 open-market sales ($14.22M) across all tracked filings.
Eben Tessari is CHIEF STRATEGY OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA). 15 SEC Form 4 filings on record going back to 2024, most recently on 8 April 2026. Most recent open-market trade: sold $9K of KNSA on 1 December 2025. Lifetime open-market sales: $14.22M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Eben Tessari.
InsiderAlpha's records for Eben Tessari go back to 2024: 15 primary Form 4 filings, an average of 5.0 per year. 20 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
